Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients with Edwards TAVR: https://lnkd.in/gu-49k_d
The Placement of Aortic Transcatheter Valves (PARTNER) is a pivotal RCTs comparing TAVR to SAVR or medical therapy in patients with severe aortic stenosis. The trial has provided critical data on the following and besides this weeks data in New York, additional data is expected at TCT 2024. • High-Risk Patients: Early PARTNER trials showed that TAVR is a viable alternative to SAVR for patients at high surgical risk. • Intermediate-Risk Patients: Subsequent trials expanded indications to intermediate-risk patients, demonstrating similar or better outcomes compared to SAVR. • Low-Risk Patients: as data continues to get compiled in this relative new group, the trials have started to compare TAVR in low-risk patients, showing promising results that could potentially broaden the use of TAVR. Again back to updated data being compiled for TCT 2024.. stay tuned to the science behind the RCT data. At the end, it will be a combination of patient needs and other factors to be evaluated by the individual heart teams to determine what is best for each patient. 😊
I’m grateful everyday for my TAVR procedure. 🙏
👍
What a great accomplishment Clcongratilations!
Thanks for sharing
Interesting!
There is nothing excellent about #TAVR when it is losing to #SAVR in a low risk RCT. When can we get back to #science? #P36Y Abbott Boston Scientific Edwards Lifesciences Medtronic #12days of #P35Y #evidenceaccountability #datatransparency #wheresthedata #noreallywheresitat